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RELATIONSHIP OF PASE TO MODERATE/VIGOROUS PHYSICAL ACTIVITY
MEASURED BY ACCELEROMETRY IN THE OSTEOARTHRITIS INITIATIVE
G.E. Ahn 1, J. Song 1, J. Lee 1, P.A. Semanik 1, R.W. Chang 1, L. Sharma 1,
C.B. Eaton 2, R.D. Jackson 3, A. Mysiw 4, D. Dunlop 1. 1Northwestern Univ.,
Chicago, IL, USA; 2Brown Univ., Providence, RI, USA; 3Ohio State Univ.,
Columbus, OH, USA; 4Denison Univ., Granville, OH, USA
Purpose: Physical activity conveys health beneﬁts for people with osteo-
arthritis (OA). Epidemiological studies often use self-reported instruments
to explore this relationship, but these measures do not effectively capture
actual time spent in physical activity in varying intensities. Public health
physical activity guidelines are tied to time spent in physical activity of
moderate/vigorous intensity. This study utilizes accelerometers to objec-
tively assess time spent in moderate/vigorous physical activity (MVPA) in
adults with knee OA.We investigated the correlation of objectivemeasures
with less burdensome subjective measures from Physical Activity Scale in
the Elderly (PASE) scores. We also evaluated the association of subjective
and objective measures to physical function.
Methods: Cross-sectional accelerometer data from 969 adults aged 55 and
above with radiographic knee OA (Kellgren-Lawrence  2 in one or both
knees) participating in the Osteoarthritis Initiative accelerometer moni-
toring ancillary study was assessed for physical activity and function.
Participants’ response to the PASE questionnaire was followed by 7 days of
accelerometer monitoring. Accelerometer measures included average
daily minutes in MVPA and average daily minutes in MVPA sessions of 10
minutes or more (MVPA bouts). Other subjective measures including
WOMAC (Western OntarioMacMaster) function, SF12 (12-Item Short Form
Health Survey) physical function, objective measure gait speed averaged
from two 20 meter walks, and covariables including demographics (age,
gender), and heath factors (BMI and waist circumference) were assessed.
Results:Mean PASE score was 149.80 (SD¼78.4) and mean accelerometer
MVPA was 15.55 minutes/day (SD¼17.18). PASE scores were modestly
correlated with average daily minutes in MVPA (r¼0.31) and MVPA bouts
(r¼0.21). PASE scores correlated better with accelerometer measures of
MVPA and MVPA bouts in participants who were particularly inactive
(characterized by older age, higher BMI, and greater waist circumference).
There were no signiﬁcant gender effects. Accelerometer measures of MVPA
and MVPA bouts compared to PASE scores had stronger correlation in
WOMAC function (r:-0.14, -0.12 versus -0.02), SF12 physical function
(r: 0.22, 0.19, versus 0.07), and gait speed (r: 0.35, 0.29, versus 0.16).
Conclusions: In this population with radiographic knee OA, modest
correlations of PASE with accelerometer MVPA assessments limit the
ability to use this self-reported instrument to explore relationships ofactivity intensity and OA. Accelerometry data are complementary and help
to better characterize the effects of physical activity on health outcomes.
Accelerometer MVPA and MVPA bouts were more strongly associated with
physical function than PASE, although that correlation was modest at best.
The choice of PASE versus objectivemeasurement for future epidemiologic
studies must take into account the purpose for which physical activity is
being measured.
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OSTEOARTHRITIS IN FRANCE THE COST OF AMBULATORY CARE IN 2010
L. Grange, Sr.1, F. Rannou, Sr. 2, P. Bertin, Sr. 3, C. Taieb, Sr. 4. 1Clinique
Univ.ire de Rhumatologie, CHU Grenoble, Grenoble, France; 2Dept. of
Rehabilitation, Inst. of Rheumatology, Paris, France; 3Ctr. de la douleur,
CHU Limoges, Limoges, France; 4 Publi Hlth., Boulogne Billancourt, France
Purpose: In France, the cost of an osteoarthritic patient has not been
estimated for several years. The aim of the study was to evaluate the
annual cost of the treatment given to osteoarthritic patients by GP.
Methods: The cohort was made up of patients who were diagnosed with
osteoarthritis between April 2009 and March 2010 (IMS Disease Analyzer
database) The cost includes all medical cost to the patients in the cohort,
and colligated in the Disease Analyzer database (all consultations with GPs
and all resulting drug prescriptions). The evaluated cost is therefore the
annual cost of treatment given to an osteoarthritic patient.
Results: 18 976 patients suffering from osteoarthritis were followed. For
these patients, who had an average age of 66, all consultations with GPs as
well as all resulting drug prescriptions were valued both in terms of
societal cost and cost to health insurance. The average annual cost of
disease management by a GP of a patient suffering from osteoarthritis is
therefore valued at V755 societal cost, of which around 60% (V447) is paid
by health insurance. The annual cost of treatment by a GP of a patient
suffering from hip osteoarthritis is signiﬁcantly lower at the societal level
(V715) than at the health insurance level (V425) compared to patients
suffering from osteoarthritis in the knee or elsewhere, despite their higher
age.
Conclusions: No literary data evaluating the cost of an osteoarthritic
patient currently exists. The closest data is that produced by a COART
France study (Le Pen and coll, Revue du rhumatisme, December 2005). The
prevalence of osteoarthritis has been estimated at around 4 million
sufferers, even though this ﬁgure may be conservative, we can estimate
that the cost of osteoarthritis treatment is around 3 billion euros. We are
sure that further data will be added to existing ones.
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INCIDENCE, RISK FACTORS AND CONSEQUENCES OF PERIPROSTHETIC
AND FEMORAL FRACTURE AMONG THOSE WHO SURVIVED TOTAL HIP
REPLACEMENT FOR MORE THAN A DECADE
J.N. Katz, E.A. Wright, M.B. Harris, E. Losina. Brigham and Women's Hosp.,
Boston, MA, USA
Purpose: To determine the incidence and risk factors for periprosthetic
and non-periprosthetic femoral fractures, as well as the risk of subsequent
hospitalization following these fractures, for a population-based cohort of
patients who had a total hip replacement (THR) in 1995-1996 and were
followed from 2006-2008.
Methods:We used Medicare claims data to assemble a cohort of Medicare
beneﬁciaries who had elective primary THR from July, 1995 through June,
1996. We obtained Medicare hospital claims for these patients through
2008. The ICD-9-CM code for periprosthetic fracture (996.44) was intro-
duced in October, 2005. We excluded periprosthetic fractures occurring in
the knee or shoulder region. We used the incidence density method to
calculate the annual incidence of each fracture. Time ‘at risk’ was deﬁned
from the beginning of observation (January 2006) to one of the three
events, whichever occurred ﬁrst: 1) death, 2) fracture or 3) end of the
observation period (December 2008). We used multivariate Cox propor-
tional hazards models to identify risk factors for periprosthetic fractures
and for non-implant related femoral fractures, including sex, age, race,
number of non-elective hospitalizations in the prior decade (a proxy for
comorbidity), eligibility for Medicaid (a proxy for low income) and number
